
- Remove this product from my favorite's list.
- Add this product to my list of favorites.
Products
Newsletter
![]() | ![]() | ![]() | ![]() | ![]() | ![]() |
Background:
VEGF165 is the most abundant splice variant of VEGF-A. VEGF165 is produced by a number of cells including endothelial cells, macrophages and T cells. VEGF165 is involved in angiogenesis, vascular endothelial cell survival, growth, migration and vascular permeability. VEGF gene expression is induced by hypoxia, inflammatory cytokines and oncogenes. VEGF165 binds to heparan sulfate and is retained on the cell surface and in the extracellular matrix. VEGF165 binds to the receptor tyrosine kinases, VEGFR1 and VEGFR2. VEGF165 is the only splice variant that binds to co-receptors NRP-1 and NRP-2 that function to enhance VEGFR2 signaling. Binding of VEGF165 to VEGFR1 and VEGFR2 leads to activation of the PI3K/AKT, p38 MAPK, FAK and paxillin. VEGF plays a key role in tumor angiogenesis in many cancers.
Source
Recombinant MABSol® Biotinylated Biotinylated Human VEGF165, epitope tag free, primary amine labeling (VE5-H8210) is expressed from human HEK293 cells. It contains AA Ala 27 - Arg 191 (Accession # NP_001165097). It is the biotinylated form of ActiveMax® Human VEGF165, Tag Free (HPLC-verified) (VE5-H4210).
Predicted N-terminus: Ala 27
Molecular Characterization
This protein carries no "tag".
The protein has a calculated MW of 19.2 kDa. As a result of glycosylation, the protein migrates as 25-30 kDa (monomer) under reducing (R) condition, and 43-50 kDa under non-reducing (NR) condition (SDS-PAGE).
Biotinylation
The primary amines in the side chains of lysine residues and the N-terminus of the protein are conjugated with biotins using standard chemical labeling method. A standard biotin reagent (13.5 angstroms) is used in this product.
Biotin:Protein Ratio
Passed as determined by the HABA assay / binding ELISA.
Endotoxin
Less than 1.0 EU per μg by the LAL method.
Purity
>95% as determined by SDS-PAGE.
Formulation
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4. Normally trehalose is added as protectant before lyophilization.
Reconstitution
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the COA.
Storage
For long term storage, the product should be stored at lyophilized state at -20°C or lower. Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
-20°C to -70°C for 24 months in lyophilized state;
-70°C for 24 months under sterile conditions after reconstitution.
Bioactivity
Please refer to product data sheet.
(1) "[Modern trends in anti-VEGF therapy for age-related macular degeneration]"
Budzinskaya, Plyukhova, Alkharki
Vestn Oftalmol (2023) 139 (3. Vyp. 2), 46-50
(2) "Chimeric Peptides from Californiconus californicus and Heterodontus francisci with Antigen-Binding Capacity: A Conotoxin Scaffold to Create Non-Natural Antibodies (NoNaBodies)"
Dueñas, Escalante, Gasperin-Bulbarela et al
Toxins (Basel) (2023) 15 (4)
(3) "Enrichment and detection of VEGF165 in blood samples on a microfluidic chip integrated with multifunctional units"
He, Xu, Wang et al
Lab Chip (2023)
Showing 1-3 of 1895 papers.
Recombinant Vascular endothelial growth factor receptor 2 (VEGF-R2), protein kinase domain, 10 µg - 450,00 €
Recombinant Vascular endothelial growth factor receptor 1 (VEGF-R1), protein kinase domain, 10 µg - 450,00 €
VEGF, 10 µg - 145,00 €
ActiveMax® Recombinant Human VEGF165 (HPLC-verified), 50µg - 442,00 €
ActiveMax® Recombinant Human VEGF121, Tag Free, 50µg - 442,00 €
Recombinant Human VEGF-C Protein, 50µg - 351,00 €
Welcome Login
Contact us
Follow us